Pieris Pharmaceuticals Q3 EPS $(0.05) Beats $(0.23) Estimate, Sales $15.132M Beat $6.42M Estimate

Pieris Pharmaceuticals (NASDAQ:PIRS) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.23) by 78.26 percent. This is a 54.55 percent increase over losses of $(0.11) per share

Benzinga · 11/11/2019 12:11

Pieris Pharmaceuticals (NASDAQ:PIRS) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.23) by 78.26 percent. This is a 54.55 percent increase over losses of $(0.11) per share from the same period last year. The company reported quarterly sales of $15.132 million which beat the analyst consensus estimate of $6.42 million by 135.70 percent. This is a 81.33 percent increase over sales of $8.345 million the same period last year.